Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: A study using thioredoxin 1 transgenic mice

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 1, 2011, Pages 239-247

  Adluri, Ram Sudheer ^a   Thirunavukkarasu, Mahesh ^a   Zhan, Lijun ^a   Akita, Yuzo ^a   Samuel, Samson Mathews ^a   Otani, Hajime ^b   Ho, Ye Shih ^c   Maulik, Gautam ^d   Maulik, Nilanjana ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c WAYNE STATE UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Myocardial infarction; Neovascularization; Oxidative stress; Thioredoxin 1; Ventricular remodeling

Indexed keywords

BETA CATENIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN AKAP 12; PROTEIN BCL 2; PROTEIN KINASE B; REGULATOR PROTEIN; SURVIVIN; THIOREDOXIN 1; THIOREDOXIN INTERACTING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; IN VIVO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WILD TYPE;

A KINASE ANCHOR PROTEINS; ANIMALS; BLOTTING, WESTERN; CARRIER PROTEINS; CELL CYCLE PROTEINS; ECHOCARDIOGRAPHY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; RANDOM ALLOCATION; THIOREDOXINS; VENTRICULAR REMODELING;

MUS; MUS MUSCULUS;

EID: 78650806850     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.11.002     Document Type: Article

References (36)

1. Molin D., Post M.J. Therapeutic angiogenesis in the heart: protect and serve. Curr Opin Pharmacol 2007, 7:158-163.
2. Losordo D.W., Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation 2004, 109:2487-2491.
3. Samuel S.M., Thirunavukkarasu M., Penumathsa S.V., Koneru S., Zhan L., Maulik G., et al. Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation 2010, 121:1244-1255.
4. Billiet L., Rouis M. Thioredoxin-1 is a novel and attractive therapeutic approach for various diseases including cardiovascular disorders. Cardiovasc Hematol Disord Drug Targets 2008, 8:293-296.
5. Ago T., Sadoshima J. Thioredoxin and ventricular remodeling. J Mol Cell Cardiol 2006, 41:762-773.
6. Piao Z.H., Yoon S.R., Kim M.S., Jeon J.H., Lee S.H., Kim T.D., et al. VDUP1 potentiates Ras-mediated angiogenesis via ROS production in endothelial cells. Cell Mol Biol (Noisy-le-grand) 2009, 55. Suppl:OL1096-103.
7. Wang Y., De Keulenaer G.W., Lee R.T. Vitamin D(3)-up-regulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J Biol Chem 2002, 277:26496-26500.
8. Mauban J.R., O'Donnell M., Warrier S., Manni S., Bond M. AKAP-scaffolding proteins and regulation of cardiac physiology. Physiology (Bethesda) 2009, 24:78-87.
9. Liu Y., Gao L., Gelman I.H. SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis. BMC Cancer 2006, 6:105.
10. Choi Y.K., Kim K.-W. AKAP12 in astrocytes induces barrier functions in human endothelial cells through protein kinase C zeta. FEBS J 2008, 275:2338-2353.
11. Choi Y.K., Kim J.H., Kim W.J., Lee H.Y., Park J.A., Lee S.-W., et al. AKAP12 regulates human blood-retinal barrier formation by downregulation of hypoxia-inducible factor-1{alpha}. J Neurosci 2007, 27:4472-4481.
12. Zhou F., Gomi M., Fujimoto M., Hayase M., Marumo T., Masutani H., et al. Attenuation of neuronal degeneration in thioredoxin-1 overexpressing mice after mild focal ischemia. Brain Res 2009, 1272:62-70.
13. Dimmeler S., Zeiher A.M. Akt takes center stage in angiogenesis signaling. Circ Res 2000, 86:4-5.
14. Tsai J.N., Lee C.H., Jeng H., Chi W.K., Chang W.C. Differential expression of glycogen synthase kinase 3 genes during zebrafish embryogenesis. Mech Dev 2000, 91:387-391.
15. Ding V.W., Chen R.H., McCormick F. Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem 2000, 275:32475-32481.
16. Thirunavukkarasu M., Han Z., Zhan L., Penumathsa S.V., Menon V.P., Maulik N. Adeno-sh-beta-catenin abolishes ischemic preconditioning-mediated cardioprotection by downregulation of its target genes VEGF, Bcl-2, and survivin in ischemic rat myocardium. Antioxid Redox Signal 2008, 10:1475-1484.
17. Kaga S., Zhan L., Altaf E., Maulik N. Glycogen synthase kinase-3beta/beta-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium. J Mol Cell Cardiol 2006, 40:138-147.
18. Vidavalur R., Swarnakar S., Thirunavukkarasu M., Samuel S.M., Maulik N. Ex vivo and in vivo approaches to study mechanisms of cardioprotection targeting ischemia/reperfusion (i/r) injury: useful techniques for cardiovascular drug discovery. Curr Drug Discov Technol 2008, 5:269-278.
19. Koneru S., Penumathsa S.V., Thirunavukkarasu M., Zhan L., Maulik N. Thioredoxin-1 gene delivery induces heme oxygenase-1 mediated myocardial preservation after chronic infarction in hypertensive rats. Am J Hypertens 2009, 22:183-190.
20. Edelberg J.M., Lee S.H., Kaur M., Tang L., Feirt N.M., McCabe S., et al. Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation 2002, 105:608-613.
21. Niehaus W.G., Samuelsson B. Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem 1968, 6:126-130.
22. Samuel S.M., Thirunavukkarasu M., Penumathsa S.V., Paul D., Maulik N. Akt/FOXO3a/SIRT1-mediated cardioprotection by n-tyrosol against ischemic stress in rat in vivo model of myocardial infarction: switching gears toward survival and longevity. J Agric Food Chem 2008, 56:9692-9698.
23. Penumathsa S.V., Koneru S., Samuel S.M., Maulik G., Bagchi D., Yet S.F., et al. Strategic targets to induce neovascularization by resveratrol in hypercholesterolemic rat myocardium: role of caveolin-1, endothelial nitric oxide synthase, hemeoxygenase-1, and vascular endothelial growth factor. Free Radic Biol Med 2008, 45:1027-1034.
24. Thirunavukkarasu M., Penumathsa S.V., Koneru S., Juhasz B., Zhan L., Otani H., et al. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 2007, 43:720-729.
25. Samuel S.M., Akita Y., Paul D., Thirunavukkarasu M., Zhan L., Sudhakaran P.R., et al. Coadministration of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats. Diabetes 2010, 59:51-60.
26. Yamawaki H., Haendeler J., Berk B.C. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ Res 2003, 93:1029-1033.
27. World C.J., Yamawaki H., Berk B.C. Thioredoxin in the cardiovascular system. J Mol Med 2006, 84:997-1003.
28. Lee S.W., Kim W.J., Choi Y.K., Song H.S., Son M.J., Gelman I.H., et al. SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat Med 2003, 9:900-906.
29. Ema M., Hirota K., Mimura J., Abe H., Yodoi J., Sogawa K., et al. Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 1999, 18:1905-1914.
30. Zhou J., Damdimopoulos A.E., Spyrou G., Brune B. Thioredoxin 1 and thioredoxin 2 have opposed regulatory functions on hypoxia-inducible factor-1alpha. J Biol Chem 2007, 282:7482-7490.
31. Hirota K., Semenza G.L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006, 59:15-26.
32. Steagall R.J., Hua F., Thirunazukarasu M., Zhan L., Li C., Maulik N., et al. Abstract 3600: HspA12B promotes angiogenesis through suppressing AKAP12 and up-regulating VEGF pathway. Circulation 2008, 118. S_449.
33. Steagall R.J., Rusinol A.E., Truong Q.A., Han Z. HSPA12B is predominantly expressed in endothelial cells and required for angiogenesis. Arterioscler Thromb Vasc Biol 2006, 26:2012-2018.
34. Hamada Y., Miyata S., Nii-Kono T., Kitazawa R., Kitazawa S., Higo S., et al. Overexpression of thioredoxin1 in transgenic mice suppresses development of diabetic nephropathy. Nephrol Dial Transplant 2007, 22:1547-1557.
35. Katare R., Andrea C., Emanueli C., Madeddu P. Benfotiamine improves functional recovery of the infarcted heart via activation of pro-survival G6PD/Akt signaling pathway and modulation of neurohormonal response. J Mol Cell Cardiol 2010, 49:625-638.
36. Kobayashi H., Yasuda S., Bao N., Iwasa M., Kawamura I., Yamada Y., et al. Postinfarct treatment with oxytocin improves cardiac function and remodeling via activating cell-survival signals and angiogenesis. J Cardiovasc Pharmacol 2009, 54:510-519.